Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon Johnson

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.
Immunity|December 20, 2018
The Innate Immune Sensor NLRC3 Acts as a Rheostat that Fine-Tunes T Cell Responses in Infection and AutoimmunityToru Uchimura, Yoshitaka Oyama, Meng Deng, et al.
Molecular Genetics & Genomic Medicine|July 3, 2018
Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics researchMadison R Bishop, Amit Shah, Melissa Shively, et al.
Physical Therapy|April 30, 2025
Physical Function Differences by COVID-19 Status: A Cross-Sectional Analysis from the RECOVER Adult CohortGrace L Kulik Née Ditzenberger, Tianyu Zheng, Sarah E Jolley, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.
Immunity|December 20, 2018
The Innate Immune Sensor NLRC3 Acts as a Rheostat that Fine-Tunes T Cell Responses in Infection and AutoimmunityToru Uchimura, Yoshitaka Oyama, Meng Deng, et al.
Molecular Genetics & Genomic Medicine|July 3, 2018
Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics researchMadison R Bishop, Amit Shah, Melissa Shively, et al.
Physical Therapy|April 30, 2025
Physical Function Differences by COVID-19 Status: A Cross-Sectional Analysis from the RECOVER Adult CohortGrace L Kulik Née Ditzenberger, Tianyu Zheng, Sarah E Jolley, et al.
Pageof 6